The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | CAR-T therapy in non-Hodgkin lymphoma: current status and future outlooks
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, briefly discusses the current status of CAR-T therapy in non-Hodgkin lymphoma (NHL), commenting on whether these agents may be moved into earlier lines or if they may play a role in consolidation. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
